Skip to main content
Erschienen in: Familial Cancer 4/2010

01.12.2010

Screening for large genomic rearrangements of the BRIP1 and CHK1 genes in Finnish breast cancer families

verfasst von: Szilvia Solyom, Katri Pylkäs, Robert Winqvist

Erschienen in: Familial Cancer | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

In search for susceptibility genes that could explain an additional portion of familial breast cancer clustering in Finland, we set out to evaluate the presence of large genomic rearrangements in two candidate genes, BRIP1 and CHK1. BRIP1 is a BRCA1 associated protein that is mutated in a fraction of familial breast cancer and Fanconi anemia cases. To date, the role of large BRIP1 deletions in breast cancer susceptibility is not well-characterized. CHK1 is a critical maintainer of cell cycle checkpoints and genomic stability, and is also involved in the BRCA1 and FA protein signalling pathways. Although CHK1 is a very important protein for cell cycle and DNA integrity maintenance control, no mutations in this gene has yet been associated with predisposition to cancer. For the present study, blood DNA from affected index persons of 111 Northern Finnish breast cancer families was assessed for possible constitutional exonic deletions or amplifications in the BRIP1 and CHK1 genes by using the multiplex ligation-dependent probe amplification method. Our results showed that exonic deletions or amplifications affecting the BRIP1 and CHK1 genes seem not to contribute to hereditary breast cancer susceptibility in the Finnish population. To our knowledge, this is the first attempt to determine the existence of large CHK1 deletions in familial breast cancer or in any disease with a hereditary background.
Literatur
1.
Zurück zum Zitat Group AnglianBreastCancerStudy (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83:1301–1308CrossRef Group AnglianBreastCancerStudy (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83:1301–1308CrossRef
2.
Zurück zum Zitat Easton DF, Pooley KA, Dunning AM et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447:1087–1093CrossRefPubMed Easton DF, Pooley KA, Dunning AM et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447:1087–1093CrossRefPubMed
3.
Zurück zum Zitat Rahman N, Stratton MR (1998) The genetics of breast cancer susceptibility. Annu Rev Genet 32:95–121CrossRefPubMed Rahman N, Stratton MR (1998) The genetics of breast cancer susceptibility. Annu Rev Genet 32:95–121CrossRefPubMed
4.
Zurück zum Zitat Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40:17–22CrossRefPubMed Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40:17–22CrossRefPubMed
6.
Zurück zum Zitat Cantor SB, Bell DW, Ganesan S et al (2001) BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105:149–160CrossRefPubMed Cantor SB, Bell DW, Ganesan S et al (2001) BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105:149–160CrossRefPubMed
7.
Zurück zum Zitat Cantor S, Drapkin R, Zhang F et al (2004) The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci 101:2357–2362CrossRefPubMed Cantor S, Drapkin R, Zhang F et al (2004) The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci 101:2357–2362CrossRefPubMed
8.
Zurück zum Zitat Seal S, Thompson D, Renwick A et al (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38:1239–1241CrossRefPubMed Seal S, Thompson D, Renwick A et al (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38:1239–1241CrossRefPubMed
9.
Zurück zum Zitat Levitus M, Waisfisz Q, Godthelp BC et al (2005) The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 37:934–935CrossRefPubMed Levitus M, Waisfisz Q, Godthelp BC et al (2005) The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 37:934–935CrossRefPubMed
10.
Zurück zum Zitat Levran O, Attwooll C, Henry RT et al (2005) The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 37:931–933CrossRefPubMed Levran O, Attwooll C, Henry RT et al (2005) The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 37:931–933CrossRefPubMed
11.
Zurück zum Zitat Litman R, Peng M, Jin Z et al (2005) BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 8:255–265CrossRefPubMed Litman R, Peng M, Jin Z et al (2005) BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 8:255–265CrossRefPubMed
12.
Zurück zum Zitat Sy SM, Huen MS, Chen J (2009) PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci 106:7155–7160CrossRefPubMed Sy SM, Huen MS, Chen J (2009) PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci 106:7155–7160CrossRefPubMed
13.
Zurück zum Zitat Zhang F, Fan Q, Ren K et al (2009) PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res 7:1110–1118CrossRefPubMed Zhang F, Fan Q, Ren K et al (2009) PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res 7:1110–1118CrossRefPubMed
14.
Zurück zum Zitat Pylkäs K, Erkko H, Nikkilä J et al (2008) Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families. BMC Cancer 8:14CrossRef Pylkäs K, Erkko H, Nikkilä J et al (2008) Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families. BMC Cancer 8:14CrossRef
15.
Zurück zum Zitat Karppinen SM, Vuosku J, Heikkinen K et al (2003) No evidence of involvement of germline BACH1 mutations in Finnish breast and ovarian cancer families. Eur J Cancer 39:366–371CrossRefPubMed Karppinen SM, Vuosku J, Heikkinen K et al (2003) No evidence of involvement of germline BACH1 mutations in Finnish breast and ovarian cancer families. Eur J Cancer 39:366–371CrossRefPubMed
16.
Zurück zum Zitat Vahteristo P, Yliannala K, Tamminen A et al (2006) BACH1 Ser919Pro variant and breast cancer risk. BMC Cancer 6:19CrossRefPubMed Vahteristo P, Yliannala K, Tamminen A et al (2006) BACH1 Ser919Pro variant and breast cancer risk. BMC Cancer 6:19CrossRefPubMed
17.
Zurück zum Zitat Yarden RI, Pardo-Reoyo S, Sgagias M et al (2002) BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 30:285–289CrossRefPubMed Yarden RI, Pardo-Reoyo S, Sgagias M et al (2002) BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 30:285–289CrossRefPubMed
18.
Zurück zum Zitat Ting NS, Lee WH (2004) The DNA double-strand break response pathway: becoming more BRCAish than ever. DNA Repair 3:935–944CrossRefPubMed Ting NS, Lee WH (2004) The DNA double-strand break response pathway: becoming more BRCAish than ever. DNA Repair 3:935–944CrossRefPubMed
19.
Zurück zum Zitat Bahassi EM, Ovesen JL, Riesenberg AL et al (2008) The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. Oncogene 27:3977–3985CrossRefPubMed Bahassi EM, Ovesen JL, Riesenberg AL et al (2008) The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. Oncogene 27:3977–3985CrossRefPubMed
20.
Zurück zum Zitat Wang X, Kennedy RD, Ray K et al (2007) Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway. Mol Cell Biol 27:3098–3108CrossRefPubMed Wang X, Kennedy RD, Ray K et al (2007) Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway. Mol Cell Biol 27:3098–3108CrossRefPubMed
21.
Zurück zum Zitat Zhi G, Wilson JB, Chen X et al (2009) Fanconi anemia complementation group FANCD2 protein serine 331 phosphorylation is important for fanconi anemia pathway function and BRCA2 interaction. Cancer Res 69:8775–8783CrossRefPubMed Zhi G, Wilson JB, Chen X et al (2009) Fanconi anemia complementation group FANCD2 protein serine 331 phosphorylation is important for fanconi anemia pathway function and BRCA2 interaction. Cancer Res 69:8775–8783CrossRefPubMed
22.
Zurück zum Zitat Guervilly JH, Mace-Aime G, Rosselli F (2008) Loss of CHK1 function impedes DNA damage-induced FANCD2 monoubiquitination but normalizes the abnormal G2 arrest in Fanconi anemia. Hum Mol Genet 17:679–689CrossRefPubMed Guervilly JH, Mace-Aime G, Rosselli F (2008) Loss of CHK1 function impedes DNA damage-induced FANCD2 monoubiquitination but normalizes the abnormal G2 arrest in Fanconi anemia. Hum Mol Genet 17:679–689CrossRefPubMed
23.
Zurück zum Zitat Stracker TH, Usui T, Petrini JH (2009) Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair 8:1047–1054CrossRefPubMed Stracker TH, Usui T, Petrini JH (2009) Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair 8:1047–1054CrossRefPubMed
24.
Zurück zum Zitat Collis SJ, Barber LJ, Clark AJ et al (2007) HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability. Nat Cell Biol 9:391–401CrossRefPubMed Collis SJ, Barber LJ, Clark AJ et al (2007) HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability. Nat Cell Biol 9:391–401CrossRefPubMed
25.
Zurück zum Zitat Efeyan A, Serrano M (2007) P53: guardian of the genome and policeman of the oncogenes. Cell Cycle 6:1006–1010PubMed Efeyan A, Serrano M (2007) P53: guardian of the genome and policeman of the oncogenes. Cell Cycle 6:1006–1010PubMed
26.
Zurück zum Zitat Puc J, Keniry M, Li HS et al (2005) Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 7:193–204CrossRefPubMed Puc J, Keniry M, Li HS et al (2005) Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 7:193–204CrossRefPubMed
27.
Zurück zum Zitat Kim CJ, Lee JH, Song JW et al (2007) Chk1 frameshift mutation in sporadic and hereditary non-polyposis colorectal cancers with microsatellite instability. Eur J Surg Oncol 33:580–585CrossRefPubMed Kim CJ, Lee JH, Song JW et al (2007) Chk1 frameshift mutation in sporadic and hereditary non-polyposis colorectal cancers with microsatellite instability. Eur J Surg Oncol 33:580–585CrossRefPubMed
28.
Zurück zum Zitat Bertoni F, Codegoni AM, Furlan D et al (1999) CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes Cancer 26:176–180CrossRefPubMed Bertoni F, Codegoni AM, Furlan D et al (1999) CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes Cancer 26:176–180CrossRefPubMed
29.
Zurück zum Zitat Menoyo A, Alazzouzi H, Espin E et al (2001) Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res 61:7727–7730PubMed Menoyo A, Alazzouzi H, Espin E et al (2001) Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res 61:7727–7730PubMed
30.
Zurück zum Zitat Papp T, Niemetz A, Dosdahl N et al (2007) Mutational analysis of Chk1, Chk2, Apaf1 and Rb1 in human malignant melanoma cell lines. Oncol Rep 17:135–140PubMed Papp T, Niemetz A, Dosdahl N et al (2007) Mutational analysis of Chk1, Chk2, Apaf1 and Rb1 in human malignant melanoma cell lines. Oncol Rep 17:135–140PubMed
31.
Zurück zum Zitat Kumar K, Rahman Q, Schipper H et al (2005) Mutational analysis of 9 different tumour-associated genes in human malignant mesothelioma cell lines. Oncol Rep 14:743–750PubMed Kumar K, Rahman Q, Schipper H et al (2005) Mutational analysis of 9 different tumour-associated genes in human malignant mesothelioma cell lines. Oncol Rep 14:743–750PubMed
32.
Zurück zum Zitat Haruki N, Saito H, Tatematsu Y et al (2000) Histological type-selective, tumor-predominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer. Cancer Res 60:4689–4692PubMed Haruki N, Saito H, Tatematsu Y et al (2000) Histological type-selective, tumor-predominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer. Cancer Res 60:4689–4692PubMed
33.
Zurück zum Zitat Marsh A, Healey S, Lewis A et al (2007) Mutation analysis of five candidate genes in familial breast cancer. Breast Cancer Res Treat 105:377–389CrossRefPubMed Marsh A, Healey S, Lewis A et al (2007) Mutation analysis of five candidate genes in familial breast cancer. Breast Cancer Res Treat 105:377–389CrossRefPubMed
34.
Zurück zum Zitat Vahteristo P, Tamminen A, Karvinen P et al (2001) p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 61:5718–5722PubMed Vahteristo P, Tamminen A, Karvinen P et al (2001) p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 61:5718–5722PubMed
35.
Zurück zum Zitat Allinen M, Peri L, Kujala S et al (2002) Analysis of 11q21–24 loss of heterozygosity candidate target genes in breast cancer: indications of TSLC1 promoter hypermethylation. Genes Chromosomes Cancer 34:384–389CrossRefPubMed Allinen M, Peri L, Kujala S et al (2002) Analysis of 11q21–24 loss of heterozygosity candidate target genes in breast cancer: indications of TSLC1 promoter hypermethylation. Genes Chromosomes Cancer 34:384–389CrossRefPubMed
36.
Zurück zum Zitat Hampton OA, Den Hollander P, Miller CA et al (2009) A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome. Genome Res 19:167–177CrossRefPubMed Hampton OA, Den Hollander P, Miller CA et al (2009) A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome. Genome Res 19:167–177CrossRefPubMed
37.
Zurück zum Zitat Ameziane N, van den Ouweland AM, Adank MA et al (2009) Lack of large genomic deletions in BRIP1, PALB2, and FANCD2 genes in BRCA1/2 negative familial breast cancer. Breast Cancer Res Treat 118:651–653CrossRefPubMed Ameziane N, van den Ouweland AM, Adank MA et al (2009) Lack of large genomic deletions in BRIP1, PALB2, and FANCD2 genes in BRCA1/2 negative familial breast cancer. Breast Cancer Res Treat 118:651–653CrossRefPubMed
38.
Zurück zum Zitat Walsh T, Casadei S, Coats KH et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295:1379–1388CrossRefPubMed Walsh T, Casadei S, Coats KH et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295:1379–1388CrossRefPubMed
Metadaten
Titel
Screening for large genomic rearrangements of the BRIP1 and CHK1 genes in Finnish breast cancer families
verfasst von
Szilvia Solyom
Katri Pylkäs
Robert Winqvist
Publikationsdatum
01.12.2010
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 4/2010
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-010-9360-7

Weitere Artikel der Ausgabe 4/2010

Familial Cancer 4/2010 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.